Ethypharm Expands in China’s IBD Market with Acquisition of Mesalazine Suppository
Ethypharm, a France-based pharmaceutical company, has announced that its Chinese subsidiary, Shanghai Ethypharmaceuticals Ltd, has...
Sihuan’s Xuanzhu Biopharmaceutical Strikes Licensing Deal with Livzon Pharmaceutical for Fadanafil
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has declared that its subsidiary, Xuanzhu Biopharmaceutical Co.,...
CStone Pharmaceuticals Gets NMPA Green Light for Local Production of Gavreto
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has announced that it...
Innovent Biologics’ IBI363 Shows Promising Results in Phase Ia/Ib Trial for Advanced Solid Tumors
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Ronovo Surgical Secures Over RMB 300 Million in Series B to Globalize Surgical Robot
Shanghai-based surgical robotics specialist, Ronovo Surgical, has reportedly raised over RMB 300 million (USD 41.3...
Cellbri Bio Secures Nearly RMB 200 Million in Series B Financing to Boost CGT Commercialization
Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy...
Zhejiang Dian Diagnostics Partners with Quest Diagnostics to Advance Alzheimer’s Disease Blood Tests
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics company based in China, has...
Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership...
GSK Partners with Ochre Bio to Access Liver Data for Hepatology Therapy Development
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow...
Pfizer’s Gene Therapy for Duchenne Muscular Dystrophy Misses Late-Stage Trial Endpoints
Pfizer Inc. (NYSE: PFE) has announced that a late-stage clinical trial for its investigational gene...
AstraZeneca’s Farxiga Receives FDA Approval for Pediatric Type-2 Diabetes Treatment
The US Food and Drug Administration (FDA) has granted regulatory approval to AstraZeneca (AZ; NASDAQ:...
Amgen’s Prolia Secures NMPA Approval for Treating Glucocorticoid-Induced Osteoporosis in High-Risk Patients
Biopharmaceutical giant Amgen has received marketing approval from China’s National Medical Products Administration (NMPA) for...
NHSA Seeks Public Input on National Reimbursement Drug List Adjustments
The National Healthcare Security Administration (NHSA) has unveiled the adjustment plan for the National Reimbursement...
Eli Lilly’s Baqsimi Gains NMPA Approval for Diabetes Hypoglycemia Treatment
The National Medical Products Administration (NMPA) in China has granted approval to Eli Lilly &...
Chia Tai Tianqing and China Resource Medicine Commercial Holdings Join Forces for Pharmaceutical Industry Expansion
Chia Tai Tianqing, a renowned name in the Chinese healthcare industry, has forged a strategic...
Boehringer Ingelheim’s Survodutide Earns Breakthrough Designation for MASH Treatment in China
Boehringer Ingelheim (BI), the German pharmaceutical colossus, has declared that it has been granted Breakthrough...
Innovent Biologics’ CLDN18.2-Targeted ADC IBI343 Earns FDA Fast-Track Status
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Zelgen Biopharmaceuticals’ Jacktinib Meets Primary Endpoint in Severe Alopecia Areata Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Joincare Pharmaceutical Receives NMPA Approval for Generic Seretide
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a leading pharmaceutical company based in China,...
WuXi AppTec and WuXi Bio Shares Rally as US Biosecure Act Excluded from Defense Bill
Shares of Chinese Contract Development and Manufacturing Organizations (CDMOs) WuXi AppTec (SHA: 603259) and WuXi...